JLPascual rates Johnson & Johnson stock Sell at USD 110.00
Published on 10/21/2026 at 10:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst pressure and operating growth
- JLPascual assigned a Sell rating and a USD 110.00 target on October 17, 2026.
- Third-quarter sales rose 5.9 percent to USD 25.40 billion on October 13, 2026.
- Johnson & Johnson stock trades at EUR 229.48 at 10:38 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.77 percent below the Xetra close of October 20, 2026.
- The next earnings report is scheduled for January 20, 2027.
Johnson & Johnson (ISIN US4781601046) was trading at EUR 229.48 at Lang & Schwarz on October 21, 2026, at 10:38 a.m. CEST, 0.77 percent below the Xetra close of October 20, 2026. According to Business Insider, analyst Jose Luis Pascual assigned the stock a Sell rating and a USD 110.00 price target on October 17, 2026.
Guidance rose with sales
Johnson & Johnson reported third-quarter 2026 sales of USD 25.40 billion, up 5.9 percent from USD 23.99 billion a year earlier. The company also lifted its full-year 2026 reported-sales guidance to a USD 101.00 billion to USD 101.40 billion range, with a USD 101.20 billion midpoint, from a prior midpoint of USD 101.10 billion, according to Johnson & Johnson on October 13, 2026.
The same release reported adjusted earnings per share of USD 2.59 for the third quarter, while reported diluted earnings per share were USD 0.09 after a one-time special charge linked to talc litigation and recent transactions.
What does MedTech mean for results?
MedTech remains the clearest counterweight to the pharmaceutical growth story. Revenue in the segment rose 2.5 percent to USD 8.64 billion in the third quarter, below the USD 8.71 billion analyst estimate cited by Reuters. Innovative Medicine sales increased 7.7 percent to USD 16.76 billion, giving the faster-growing segment greater weight in the quarter.
Three dates define the sequence
On October 13, 2026, Johnson & Johnson reported USD 25.40 billion in third-quarter sales and raised its 2026 guidance. On October 15, 2026, Bernstein raised its price target from USD 261.00 to USD 270.00 while maintaining Market Perform, according to Investing.com. On October 17, 2026, JLPascual assigned a Sell rating and a USD 110.00 target, as reported by Business Insider.
Next earnings date is set
The next reporting date is scheduled for January 20, 2027, according to Public.com. For investors, the key tension is clear: Innovative Medicine is growing faster than MedTech, while the latest analyst target sits far below the current euro quotation.
Stock remains below its yearly high
Johnson & Johnson stock was trading at EUR 229.48 at Lang & Schwarz on October 21, 2026, at 10:38 a.m. CEST, 0.77 percent below the Xetra close of October 20, 2026 at EUR 231.25. The primary listing is on the NYSE, where the stock was last quoted at USD 259.36 on October 20, 2026, and the 52-week range was USD 184.66 to USD 281.07.
The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.
Johnson & Johnson key data
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 21, 2026, 10:38 a.m. CEST): EUR 229.48
- Change versus Xetra close: minus 0.77 percent
- Xetra close (October 20, 2026): EUR 231.25
- Market capitalization: USD 625.0 billion (as of October 20, 2026)
- 52-week range: EUR 158.56-EUR 242.00 (as of October 21, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
Market context: Market report S&P 500.
